Curative or non-curative: immunotherapy for advanced melanoma
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkaf041 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Richard Kelly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Paula Fox Melanoma and Cancer Centre, The Alfred, Melbourne, Australia. Hauptthemen laut MEDLINE: Melanoma, Immunotherapy, Skin Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Government Research Training Program.
Abstract (Originalsprache)
Advanced melanoma was historically considered incurable; however, a 52% 10-year melanoma-specific survival rate from seminal immunotherapy trials challenges that conclusion.1 There is no literature exploring clinicians’ discussion of treatment intent with patients, or whether this represents cure. We performed a multicenter retrospective cohort analysis to examine treatment intent, using electronic medical records to identify 278 patients with unresectable or stage IV melanoma consented for immunotherapy from 2019 to 2023. Thirty-two (12%) were consented for curative-intent treatment (CIT). CIT frequency was not significantly influenced by patient or disease characteristics. Patients consented for CIT received significantly higher rates of combination immunotherapy than patients consented for non-curative-intent treatment (NCIT), 76% (16/21) vs 47% (116/246), P = .022. Among 267 unresectable patients, CIT rates differed significantly between Victoria and South Australia, 14% (20/142) vs 0.8% (1/125), P < .001. Our data confirms variability of documented treatment-intent in advanced melanoma. Further research is needed to understand how this affects patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paula Fox Melanoma and Cancer Centre, The Alfred, Melbourne, Australia.
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
- The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Adelaide, South Australia.
ORCID-Profile: Richard Kelly, Abigail Miller, Andrew Haydon
Förderung
- Australian Government Research Training Program
Zitieren
APA
Kelly, R., Miller, A., Roberts-Thomson, R., & Haydon, A. (2025). Curative or non-curative: immunotherapy for advanced melanoma. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf041
Vancouver
Kelly R, Miller A, Roberts-Thomson R, Haydon A. Curative or non-curative: immunotherapy for advanced melanoma. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf041
BibTeX
@article{Kelly2025,
author = {Kelly, Richard and Miller, Abigail and Roberts-Thomson, Rachel and Haydon, Andrew},
title = {Curative or non-curative: immunotherapy for advanced melanoma},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkaf041}
}
EUVIMED